TAK-418   Click here for help

GtoPdb Ligand ID: 11516

Compound class: Synthetic organic
Comment: TAK-418 is an orally administered, brain-penetrant lysine-specific demethylase 1 (LSD1; KDM1A) inhbitor that was developed by Takeda for potential to treat neurodevelopmental disorders [1-2]. The compound is proposed to correct the persistent epigenetic dysregulation (thus restoring gene expression homeostasis) that is believed to underlie the pathophysiology of neurodevelopmental disorders such as autism spectrum disorder.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 4
Hydrogen bond donors 2
Rotatable bonds 7
Topological polar surface area 78.6
Molecular weight 320.16
XLogP 1.22
No. Lipinski's rules broken 0
SMILES / InChI / InChIKey
Click here for help
Canonical SMILES O=C(c1csc(c1)[C@@H]1C[C@H]1NCC1CC1)NC1CCOCC1
Isomeric SMILES O=C(c1csc(c1)[C@@H]1C[C@H]1NCC1CC1)NC1CCOCC1
InChI InChI=1S/C17H24N2O2S/c20-17(19-13-3-5-21-6-4-13)12-7-16(22-10-12)14-8-15(14)18-9-11-1-2-11/h7,10-11,13-15,18H,1-6,8-9H2,(H,19,20)/t14-,15-/m1/s1
InChI Key QZNGFWQWWSECMG-HUUCEWRRSA-N
No information available.
Summary of Clinical Use Click here for help
Phase 1 studies of TAK-418 in healthy volunteers have been completed without reports of safety issues, but development appears to have been terminated as TAK-418 is no longer included in Takeda's pipeline of